Calidi Biotherapeutics, Inc.
CLDWW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCLDI
13F holders, Q3 2023
Institutional positions in Calidi Biotherapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- 0 vs. Q2 2023
- Shares held
- 6.18M
- −351.0K (−5.4%) vs. Q2 2023
- Total value
- $1.64M
- +$773.0K (+89.2%) vs. Q2 2023
- New holders
- 6
- 0 more added
- Sold out
- 6
- 5 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDWW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $1.01K |
| Q3 2024 | 16 | $99.4K |
| Q2 2024 | 17 | $281.5K |
| Q1 2024 | 17 | $385.1K |
| Q4 2023 | 18 | $384.0K |
| Q3 2023 | 22 | $1.64M |
| Q2 2023 | 22 | $866.3K |
| Q1 2023 | 24 | $366.1K |
| Q4 2022 | 25 | $350.0K |
| Q3 2022 | 27 | $479.9K |
| Q2 2022 | 28 | $767.0K |
| Q1 2022 | 29 | $2.83M |
| Q4 2021 | 23 | $3.01M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Calidi Biotherapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nomura Holdings Inc | 467,818 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 50 | $11 | 0.00% | +50 | New |
| The PNC Financial Services Group, Inc. | 50 | $11 | 0.00% | +50 | New |
| UBS Group AG | 80 | $18 | 0.00% | −2,709−97.1% | Reduced |
| Clear Street LLC | 1,946 | $428 | 0.00% | +1,946 | New |
| Sea Otter Advisors LLC | 4,871 | $1.07K | 0.00% | +4,871 | New |
| Bank of Montreal | 12,500 | $4.01K | 0.00% | 00.0% | Unchanged |
| Walleye Trading LLC | 20,052 | $4.41K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 36,469 | $8.02K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 66,111 | $14.5K | 0.00% | −18,470−21.8% | Reduced |
| Ionic Capital Management LLC | 75,172 | $16.5K | 0.01% | −159,741−68.0% | Reduced |
| Cowen and Company, LLC | 100,000 | $22.0K | 0.00% | −3,678−3.5% | Reduced |
| Exos TFP Holdings LLC | 105,000 | $23.1K | 0.01% | +105,000 | New |
| EHP Funds Inc. | 187,914 | $41.3K | 0.02% | 00.0% | Unchanged |
| Periscope Capital Inc. | 200,000 | $44.0K | 0.00% | −209,800−51.2% | Reduced |
| Arena Investors LP | 333,333 | $73.3K | 0.09% | 00.0% | Unchanged |
| Aristeia Capital LLC | 494,400 | $116.2K | 0.00% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 600,000 | $132.0K | 0.01% | 00.0% | Unchanged |
| Shaolin Capital Management LLC | 650,000 | $143.0K | 0.01% | +650,000 | New |
| Finepoint Capital LP | 655,200 | $144.1K | 0.07% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | – | $342.3K | 0.02% | – | – |
| Polar Asset Management Partners Inc. | 2,165,086 | $508.8K | 0.01% | 00.0% | Unchanged |
| Radcliffe Capital Management, L.P. | 0 | $0 | 0.00% | −264,799−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −353,227−100.0% | Sold out |
| CNH Partners LLC | 0 | $0 | 0.00% | −49,304−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −15,400−100.0% | Sold out |
| Flow Traders U.S. LLC | 0 | $0 | 0.00% | −10,837−100.0% | Sold out |
| Segantii Capital Management Ltd | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |